Distribution and Listing of AddLife on Nasdaq Stockholm

The Board of Directors of Addtech AB (publ) (“Addtech”) has decided to propose
that Addtech’s shares in AddLife AB (publ) (“AddLife”) to be distributed to
Addtech’s shareholders and that the Class B share in AddLife to be listed on
Nasdaq Stockholm (“Distribution”). Nasdaq Stockholm has decided to admit
AddLife’s Class B shares to trading, subject to customary conditions.

Extraordinary General Meeting of Addtech

An Extraordinary General Meeting to decide on the Distribution will be held on
March 9, 2016 and the first day of trading in AddLife shares of Class B is
expected to be March 16, 2016. Notice to attend the Extraordinary General
Meeting on March 9, 2016 has been published separately.

Background and reasons for the Distribution and listing

On June 4, 2015 Addtech announced its intention to distribute Addtech’s shares
in AddLife, previously the Life Science business area within the Addtech Group,
to Addtech’s shareholders and to list AddLife on Nasdaq Stockholm. The Boards of
Directors of Addtech and AddLife consider that AddLife is now ready to take the
step to become an independent listed company.

Addtech acquired the operations in AddLife in 2005. Since then it has performed
very well and now has estimated annual sales of approximately SEK 1.7 billion*
with good profitability. AddLife currently has strong market positions in
several Life Science niche areas in the Nordic region. To capitalise on the
strategic and operational opportunities in AddLife’s markets and to take
advantage of opportunities for growth, both organically and through
acquisitions, it is a logical step to spin-off AddLife from Addtech by listing
AddLife on Nasdaq Stockholm.

A listing of AddLife opens up excellent opportunities to increase the company’s
exposure and focus on the Life Science market. The visibility of both Addtech
and AddLife will increase by focusing and streamlining operations in this way,
which will be beneficial in relation to suppliers, customers and the labour
market, and also improve the ability to attract acquisition candidates. The spin
-off will benefit both AddLife and Addtech, allowing each company to focus on
its respective core market.

AddLife sells primarily to Nordic healthcare providers, largely through public
procurement. This type of sales has limited connection to the rest of Addtech’s
business, which focuses on industrial markets. Separating the businesses will
increase the opportunity for long-term profitable growth for both companies.
Moreover, the division will make it easier to analyse each business separately,
while allowing shareholders to adjust their holdings in Addtech and AddLife,
respectively, based on personal preference.

*Based on combined net sales 2014/2015 for AddLife including Mediplast AB and
Fenno Medical OY, which were acquired in July 2015. Net sales for Mediplast and
Fenno Medical refer to conditions on a full-year basis at the time of
acquisition.

Implementation of Distribution

The spin-off will be carried out by distributing Addtech’s shares in AddLife to
the shareholders of Addtech. Each four (4) Class A shares in Addtech will
entitle the holder to one (1) Class A share in AddLife and each four (4) Class B
shares in Addtech will entitle the holder to one (1) Class B share in AddLife.
If the shareholding in Addtech is not evenly divisible by four, the holder will
receive a fraction of a share. This fraction will be added together with the
fractions held by other shareholders into whole shares in AddLife, which will be
sold on Nasdaq Stockholm through Handelsbanken. The proceeds, without deduction
of any commissions, will be paid via Euroclear Sweden.

New issue of shares in AddLife in connection with the listing

In connection with the Distribution and the listing, AddLife will conduct a
rights issue of about SEK 300 million with preferential rights for existing
shareholders (”the Issue”). The purpose of the Issue is to create a financial
base for continued profitable growth through acquisitions.

The Prospectus

A prospectus for the listing of AddLife’s shares of Class B on Nasdaq Stockholm
and the Issue will be prepared by AddLife. The prospectus is expected to be
published around March 15, 2016.

Information for the Extraordinary General Meeting in Addtech

Information material for the Extraordinary General Meeting in Addtech will be
available on Addtech’s website (under the menu Investors/Corporate
governance/General Meeting of Shareholders) about two weeks before the
Extraordinary General Meeting of Shareholders in Addtech.

Preliminary timetable

23 February           Information for the Extraordinary General Meeting will be
available

9 March                 Extraordinary General Meeting of Addtech and last day of
trading in the Addtech share with the right to distribution

10 March               First day of trading in the Addtech share without the
right to participate in the distribution

11 March               Record date in Addtech regarding the right to receive
shares in AddLife

15 March               Prospectus published

16 March               First day of trading in the AddLife share of Class B on
Nasdaq Stockholm

30 March               Publication of the full terms and conditions of the Issue

4 April                    Last day of trading in the AddLife share including
subscription rights

5 April                    First day of trading in the AddLife share excluding
subscription rights

6 April                    Record date in AddLife for the Issue

11 – 25 April          Subscription period

11 – 21 April          Trading in subscription rights (Class B) on Nasdaq
Stockholm

28 April                  Publication of the Issue results

3 May                    First day of trading for AddLife shares of Class B
issued in the Issue

Advisers

Handelsbanken Capital Markets is the financial adviser in connection with the
listing and the Issue. Advokatfirman Delphi is the legal adviser.

Stockholm, 16 February, 2016

Addtech AB (publ)

For further information, contact
Johan Sjö, President, Addtech AB, +46 8 470 49 00